GSG2 Promotes Development and Predicts Poor Prognosis of Ovarian Cancer
Authors Huang Y, Liu Y, Zhu K, Ma X, Lu R, Zhang M
Received 30 July 2020
Accepted for publication 17 December 2020
Published 19 January 2021 Volume 2021:13 Pages 499—508
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Xueqiong Zhu
Yan Huang,1,2,* Yixuan Liu,2,3,* Keyu Zhu,2,3,* Xiaolu Ma,2,3 Renquan Lu,2,3 Meiqin Zhang1,2
1Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 3Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Renquan Lu
Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, 270 Dong’An Road, Shanghai 200032, People’s Republic of China
Tel +86 18017312789
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dong’An Road, Shanghai 200032, People’s Republic of China
Tel +86 18017312218
Fax +86 21-64175590
Purpose: Ovarian cancer is one of the most common malignant tumors in gynecology, whose treatment was seriously limited by the unclear understanding of molecular mechanism in disease development. GSG2, also known as Haspin, is a novel molecule found to be involved in human cancers.
Materials and Methods: In this study, immunohistochemical analysis was used to detect GSG2 expression in ovarian cancer tissues and corresponding normal tissues. Statistical analysis was performed to construct relationship between GSG2 and tumor characteristics as well as prognosis. Ovarian cell model with GSG2 knockdown was constructed through lentivirus-mediated transfection of shRNA, which was used in MTT assay, colony formation assay and flow cytometry for investigating the role of GSG2 in ovarian cancer. A human apoptosis antibody array was used to identify potential downstream apoptosis-related proteins of GSG2.
Results: The results demonstrated the upregulation of GSG2 in ovarian cancer, whose expression was positively related to tumor grade and AJCC stage, and negatively correlated with patients’ prognosis. Moreover, knockdown of GSG2 inhibited ovarian cancer development through suppressing cell growth and inducing cell apoptosis. Further exploration revealed that a variety of apoptosis-related and PI3K signaling pathway-related proteins may be implicated in the GSG2 induced regulation of ovarian cancer.
Conclusion: In summary, it was illustrated that GSG2 was involved in the development of ovarian cancer, which has the potential to become therapeutic target and prognostic indicator in ovarian cancer treatment.
Keywords: ovarian cancer, GSG2, prognosis, cell proliferation, cell apoptosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]